We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker (BRKR) Hits a New 52-Week High: What's Driving It?
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) scaled a new 52-week high of $75.82 on Jun 16, before closing the session marginally lower at $73.99.
The company’s shares have charted a solid trajectory in recent times, appreciating 79.3% over the past year, ahead of 69.9% growth of the industry it belongs to and 38.5% rise of the S&P 500 composite.
The company is witnessing an upward trend in its stock price, prompted by solid growth potential of CALID Group. Moreover, Bruker’s MALDI Biotyper is witnessing increasing demand, which is encouraging. Further, the raised 2021 guidance boosted by the solid first-quarter performance instills investors’ confidence in the stock. However, stiff competition and forex woes are concerns.
Let’s delve deeper.
Key Growth Drivers
CALID Group Holds Potential: Bruker’s CALID Group has been making decent progress of late. The growth in CALID Group revenues during the first quarter of 2021 reflected strong demand for life science mass spectrometry and FTIR/NIR/Raman molecular spectroscopy products. Further, the company recorded robust order and revenue growth for its timsTOF unbiased 4D proteomics platform along with improved demand for other mass spec products.
High Potential of MALDI Biotyper: The demand for Bruker’s MALDI Biotyper is increasing in applied markets, specifically for food, feed and beverage. Based on the recent developments witnessed in this product portfolio, management believes Bruker is poised to double its microbiology business over the next four to five years. Given an increase in the aging population, a higher number of individuals are likely to fall prey to illnesses, especially those caused by microorganisms. We believe MALDI Biotyper is thus positioned well to contribute significantly to the company’s top line over time.
Image Source: Zacks Investment Research
Raised Guidance: Investors are upbeat about Bruker’s raised 2021outlook boosted by its strong first-quarter performance.
For 2021, Bruker expects revenue growth of approximately 14-16%, up from the previously issued guidance of 11-13%. Organic revenue growth is projected within 11-13%, up from the earlier guided range of 7-9%.
The company expects full-year adjusted earnings per share in the band of $1.82-$1.87, indicating an uptick of 35-39% from the 2020 reported figure (up from the previous expectation of $1.72-$1.77.
Downsides
Exposed to Currency Movement: Bruker conducts 80% of its business in international markets. Thus, currency fluctuations continue to result in foreign currency transaction losses.
Competitive Landscape: Bruker faces substantial competition in a consolidating industry and expects competition in all markets to increase further. Bruker BioSpin competes with companies that offer magnetic resonance spectrometers, mainly JEOL and Oxford Instruments. In the field of preclinical imaging, Bruker BioSpin faces competitive threat from Perkin Elmer, Mediso, Trifoil, MR Solutions, RS2D, Visualsonics (Fuji Film) and others.
Zacks Rank and Key Picks
Currently, Bruker carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are National Vision Holdings, Inc. (EYE - Free Report) , Envista Holdings Corporation (NVST - Free Report) and Phibro Animal Health Corporation (PAHC - Free Report) . While National Vision sports a Zacks Rank #1 (Strong Buy), Envista Holdings and Phibro Animal Health carry a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
National Vision has an expected long-term earnings growth rate of 23%.
Envista Holdings has an expected long-term earnings growth rate of 26%.
Phibro Animal Health has a projected long-term earnings growth rate of 11%.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Image: Bigstock
Bruker (BRKR) Hits a New 52-Week High: What's Driving It?
Bruker Corporation (BRKR - Free Report) scaled a new 52-week high of $75.82 on Jun 16, before closing the session marginally lower at $73.99.
The company’s shares have charted a solid trajectory in recent times, appreciating 79.3% over the past year, ahead of 69.9% growth of the industry it belongs to and 38.5% rise of the S&P 500 composite.
The company is witnessing an upward trend in its stock price, prompted by solid growth potential of CALID Group. Moreover, Bruker’s MALDI Biotyper is witnessing increasing demand, which is encouraging. Further, the raised 2021 guidance boosted by the solid first-quarter performance instills investors’ confidence in the stock. However, stiff competition and forex woes are concerns.
Let’s delve deeper.
Key Growth Drivers
CALID Group Holds Potential: Bruker’s CALID Group has been making decent progress of late. The growth in CALID Group revenues during the first quarter of 2021 reflected strong demand for life science mass spectrometry and FTIR/NIR/Raman molecular spectroscopy products. Further, the company recorded robust order and revenue growth for its timsTOF unbiased 4D proteomics platform along with improved demand for other mass spec products.
High Potential of MALDI Biotyper: The demand for Bruker’s MALDI Biotyper is increasing in applied markets, specifically for food, feed and beverage. Based on the recent developments witnessed in this product portfolio, management believes Bruker is poised to double its microbiology business over the next four to five years. Given an increase in the aging population, a higher number of individuals are likely to fall prey to illnesses, especially those caused by microorganisms. We believe MALDI Biotyper is thus positioned well to contribute significantly to the company’s top line over time.
Raised Guidance: Investors are upbeat about Bruker’s raised 2021outlook boosted by its strong first-quarter performance.
For 2021, Bruker expects revenue growth of approximately 14-16%, up from the previously issued guidance of 11-13%. Organic revenue growth is projected within 11-13%, up from the earlier guided range of 7-9%.
The company expects full-year adjusted earnings per share in the band of $1.82-$1.87, indicating an uptick of 35-39% from the 2020 reported figure (up from the previous expectation of $1.72-$1.77.
Downsides
Exposed to Currency Movement: Bruker conducts 80% of its business in international markets. Thus, currency fluctuations continue to result in foreign currency transaction losses.
Competitive Landscape: Bruker faces substantial competition in a consolidating industry and expects competition in all markets to increase further. Bruker BioSpin competes with companies that offer magnetic resonance spectrometers, mainly JEOL and Oxford Instruments. In the field of preclinical imaging, Bruker BioSpin faces competitive threat from Perkin Elmer, Mediso, Trifoil, MR Solutions, RS2D, Visualsonics (Fuji Film) and others.
Zacks Rank and Key Picks
Currently, Bruker carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are National Vision Holdings, Inc. (EYE - Free Report) , Envista Holdings Corporation (NVST - Free Report) and Phibro Animal Health Corporation (PAHC - Free Report) . While National Vision sports a Zacks Rank #1 (Strong Buy), Envista Holdings and Phibro Animal Health carry a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
National Vision has an expected long-term earnings growth rate of 23%.
Envista Holdings has an expected long-term earnings growth rate of 26%.
Phibro Animal Health has a projected long-term earnings growth rate of 11%.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>